Copenhagen, 2013-03-08 14:30 CET (GLOBE NEWSWIRE) -- Investor News
No. 2/2013
─ A conference call and live webcast to be hosted by management
on Thursday 14 March 2013 at 14:00 CET/ 9:00 EST
Copenhagen, 8 March 2012 ─ Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) announces the release of the company’s Full Year results and Annual Report for 2012 on Thursday, 14 March 2012 before 9:00am CET.
Conference call – Thursday, 14 November at 14:00 CET/ 9:00 EST
On the day, David Solomon, President and Chief Executive Officer, Mats Blom, Chief Financial Officer and Hanne Leth Hillman, Vice President and Head of IR and Corporate Communication, will host a conference call at 14:00 CET/ 9:00 EST to present the Full Year results and Annual Report for 2012, followed by a Q&A session.
The conference call will be conducted in English and the dial-in numbers are:
DK toll free +45 8088 8649
DK standard access +45 3272 9273
UK and international +44 (0) 20 3003 2666
US +1 866 966 5335
A live audio cast of the call including an accompanying slide presentation will be available via the following link: http://livecast.wehay.com/playontv/130314/zealandpharma/, which can also be accessed from the Investor section of the company’s website (www.zealandpharma.com). Participants are advised to register for the audio cast approximately 10 minutes before the start.
A replay of the event will also be made available from the Investor section of Zealand Pharma’s website following the call.
# # #
For further information, please contact:
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication
Tel: +45 5060 3689, hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2013).
Zealand Pharma has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. For further information: www.zealandpharma.com
